Gilead misses key goal in NASH liver disease trial, shares sink


By Julie Steenhuysen

CHICAGO, Feb 11 (Reuters) - Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.

The study compared the drug, called selonsertib, with a placebo treatment in a trial of nearly 900 patients with compensated cirrhosis, an advanced form of Nonalcoholic Steatohepatitis, or NASH.

Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as populations with fatty diets increasingly develop the disease.

This article appears in: World Markets , Stocks , Technology
Referenced Symbols: GILD

More from Reuters


See Reuters News

Research Brokers before you trade

Want to trade FX?